After-Hours Movers 7/31: Elan (ELN)/Biogen (BIIB) Fall on More TYSABRI PML Issues; USA Mobility (USMO) Up on Results

July 31, 2008 6:02 PM EDT

StreetInsider.com After-Hours Movers:

TomoTherapy (Nasdaq: TOMO) 43% LOWER; reports a Q2 loss of $0.12, 12 cents lower than the analyst estimate of $0.00. Revenues for the quarter were $52 million, versus the consensus of $54.78 million. Sees FY08 revs of $190-$210 million, versus the consensus of $261.6 million. Sees Q3 revs below Q1. Sees FY08 loss of $0.28-$0.43, versus the consensus of $0.14 gain.

Elan Corporation (NYSE: ELN) 34% LOWER; Biogen and Elan notified relevant regulatory agencies of two confirmed cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with TYSABRI in the commercial setting.

USA Mobility (Nasdaq: USMO) 23% HIGHER; reports Q2 EPS of $0.37, 10 cents better than the analyst estimate of $0.27. Revenues for the quarter were $92.1 million, versus the consensus of $91.20 million. Announces a $50 million buyback. Sees FY08 revenue $355-$360 million versus prior guidance $345 to $355 million, consensus is $355 million.

Nanometrics (Nasdaq: NANO) 19% LOWER; reports a Q2 loss of $0.24 adjusted, 16 cents below the analyst estimate of ($0.08). Revenues for the quarter were $23.8 million, versus the consensus of $31.50 million.

thinkorswim Group Inc. (Nasdaq: SWIM) 15% HIGHER; reports Q2 EPS of $0.27, 10 cents better than the analyst estimate of $0.17. Revenues for the quarter were $97 million, versus the consensus of $88.05 million. Announces a buyback of up to 5 million shares

Biogen Idec (Nasdaq: BIIB) 15% LOWER; Biogen and Elan notified relevant regulatory agencies of two confirmed cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with TYSABRI in the commercial setting.

Chordiant Software (Nasdaq: CHRD) 11% HIGHER; reports Q3 EPS of $0.08, 7 cents better than the analyst estimate of $0.01. Revenues for the quarter were $30.7 million, versus the consensus of $26.34 million. Sees FY08 EPS of $0.18-$0.25, versus the consensus of $0.18 and revs of $114-$117 million, versus the consensus of $112.8 million.

Genoptix (Nasdaq: GXDX) 9.6% HIGHER; reports Q2 EPS of $0.18, ex-items, 1 cent better than the analyst estimate of $0.17. Revenues for the quarter were $27.8 million, versus the consensus of $22.69 million. Sees FY08 revs of $105-$108 million, versus prior guidance of $90-$95 million, versus the consensus of $94.6 million. EPS for the year go to $1.11-$1.16, versus the consensus of $0.98.

Hansen Medical, Inc. (Nasdaq: HNSN) 8% LOWER; reports a Q2 loss of $0.61, 11 cents lower than the analyst estimate of ($0.50). Revenues for the quarter were $5.8 million, versus the consensus of $7.38 million.

Dolby Laboratories, Inc. (NYSE: DLB) 7.5% HIGHER; reports Q2 EPS of $0.40, 10 cents better than the analyst estimate of $0.30. Revenues for the quarter were $154.3 million, versus the consensus of $140.66 million. Sees FY08 revs of $605-$625 million, versus the consensus of $610 million

Gen-Probe (Nasdaq: GPRO) 5% HIGHER; reports Q2 EPS of $0.45, 9 cents better than the analyst estimate of $0.36. Revenues for the quarter were $113.7 million, versus the consensus of $106.49 million. Sees FY08 EPS $1.83 to $1.87 versus $1.76.

ValueClick, Inc. (Nasdaq: VCLK) 5% LOWER; reports Q2 EPS of $0.17, versus the analyst estimate of $0.17. Revenues for the quarter were $163.8 million, versus the consensus of $165.09 million. Sees Q3 EPS 14-15 cents versus 16 cents. Sees FY08 EPS 69-71 cents versus 74 cents.

Chesapeake Energy Corporation (NYSE: CHK) 2.3% LOWER; reports Q2 EPS of $0.89, 1 cent better than the analyst estimate of $0.88. Revenues for the quarter were $2.23 billion, versus the consensus of $2.24 billion.

Get This Report E-Mailed To You Daily and Much, Much More With StreetInsider.com Premium - FREE TRIAL

Related Categories

Special Reports

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?